Multiple Endocrine Neoplasia Type 1 (MEN1)

Table of Contents

  1. Overview
  2. Genetics and Pathogenesis
  3. Parathyroid Disease
  4. Pancreatic and GI Neuroendocrine Tumors
  5. Pituitary Adenomas
  6. Other Manifestations
  7. Diagnosis and Surveillance
  8. Treatment
  9. Prognosis and Genetic Counseling
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Overview

Multiple Endocrine Neoplasia Type 1 (MEN1), also historically called Werner syndrome after the physician who first described familial clustering of pituitary tumors with peptic ulcers in 1954, is an autosomal dominant hereditary tumor syndrome defined by the development of tumors in at least two of three classic endocrine sites: the parathyroid glands, the pancreatic and gastrointestinal neuroendocrine cells, and the anterior pituitary gland. This constellation is captured in the mnemonic of the three P's — parathyroid, pancreatic/GI neuroendocrine tumors (pNETs), and pituitary.

MEN1 is rare but clinically important. Its prevalence is approximately 1 in 30,000 in the general population, affecting men and women equally. Penetrance is near complete by age 50, meaning that nearly all individuals who carry a germline MEN1 mutation will develop at least one component tumor if they live into middle age. The condition can present in childhood or adolescence — hypercalcemia due to parathyroid hyperplasia in a teenager is one of the classic clinical clues that should prompt MEN1 genetic evaluation.

The practical consequence of recognizing MEN1 is significant. Unlike sporadic endocrine tumors, MEN1-associated tumors are typically multiple, bilateral, and prone to recurrence after surgery. Treatment strategies and surveillance protocols differ substantially from those used for sporadic counterparts. Identifying one MEN1 component tumor should trigger systematic screening for the others, and confirming a germline MEN1 mutation should initiate cascade testing among first-degree relatives.

Back to Table of Contents

Genetics and Pathogenesis

MEN1 is caused by germline loss-of-function mutations in the MEN1 tumor suppressor gene located on chromosome 11q13. This gene encodes menin, a 610-amino-acid nuclear protein that functions as a scaffold protein involved in histone modification and chromatin remodeling. Menin interacts with histone methyltransferase complexes (particularly the MLL/SET1 complex responsible for H3K4 trimethylation) to regulate transcription of genes controlling cell proliferation, apoptosis, and DNA repair. Loss of menin disrupts this chromatin-regulatory function, allowing uncontrolled proliferation of susceptible endocrine cells.

Tumor development in MEN1 follows the classic Knudson two-hit model for tumor suppressor genes. Affected individuals inherit one defective copy of MEN1 in every cell (the first hit). Tumorigenesis occurs when a somatic event — a point mutation, deletion, or loss of heterozygosity — inactivates the remaining wild-type allele in a susceptible endocrine cell (the second hit). The resulting cell, now with no functional menin, loses growth control and gives rise to a tumor. Because somatic second hits are random and independent events occurring in trillions of cells over a lifetime, multiple tumors arise at different times and in different endocrine glands — explaining the characteristic multiplicity and metachronous (asynchronous) timing of MEN1 neoplasms.

More than 1,300 distinct germline MEN1 mutations have been catalogued. Frameshift mutations (due to small insertions or deletions) and nonsense mutations (premature stop codons) are the most common classes, together accounting for roughly 75% of identified mutations; missense mutations, splice-site mutations, and large deletions make up the remainder. Germline MEN1 mutations are identified by sequencing in approximately 70–90% of patients who fulfill clinical diagnostic criteria. The remaining 10–30% of clinical MEN1 cases are either attributable to mutations in regulatory regions not captured by standard coding-sequence analysis, somatic mosaicism, or mutations in other genes such as CDKN1B (encoding p27, associated with the rarer MEN4 syndrome). Approximately 10% of MEN1 mutations arise de novo, meaning affected individuals have no family history.

Back to Table of Contents

Parathyroid Disease — the Earliest and Most Penetrant Feature

Primary hyperparathyroidism (PHPT) due to parathyroid hyperplasia is the most common and earliest manifestation of MEN1, occurring in 90–100% of mutation carriers over a lifetime. It is typically the first endocrine abnormality to appear, often becoming biochemically detectable in the second or third decade of life. The diagnosis of primary hyperparathyroidism in a patient younger than 30 — and especially in a teenager — is a strong clinical signal that should prompt MEN1 evaluation even in the absence of a family history.

The parathyroid disease of MEN1 differs fundamentally from sporadic PHPT in its pathology. In sporadic PHPT, a single parathyroid adenoma is responsible in 85–90% of cases. In MEN1-associated PHPT, all four parathyroid glands are typically hyperplastic — a multigland process reflecting the widespread first-hit predisposition carried in every cell. This multigland nature has critical surgical implications: focused minimally invasive parathyroidectomy (which is highly effective for sporadic single-gland adenoma) is generally inappropriate for MEN1, where removing only one abnormal gland leaves three others destined to develop autonomous secretion.

The clinical consequences of MEN1-associated PHPT are identical to those of sporadic hypercalcemia: nephrolithiasis (kidney stones, occurring in 15–20% of MEN1 patients with PHPT), osteoporosis with increased fracture risk, and the nonspecific symptoms of hypercalcemia (fatigue, cognitive dulling, constipation, polydipsia, polyuria). Severe symptomatic hypercalcemia (serum calcium above 12 mg/dL) is less common than in sporadic PHPT. Of note, hypercalcemia from MEN1-associated PHPT can complicate management of gastrinoma (Zollinger-Ellison syndrome): hypercalcemia itself stimulates gastrin release, worsening the acid-hypersecretory state. Treating PHPT may therefore partially ameliorate ZES symptoms.

Surgical management favors subtotal parathyroidectomy (removal of 3.5 glands, leaving a well-vascularized remnant of approximately 50 mg) or total parathyroidectomy with autotransplantation of parathyroid tissue into a forearm muscle, which allows easy re-access if the remnant becomes overactive. Both approaches have higher recurrence rates than sporadic PHPT surgery — approximately 50% of patients develop recurrent hypercalcemia within 10–12 years — reflecting continued growth pressure on remaining parathyroid tissue under MEN1 genetic predisposition.

Back to Table of Contents

Pancreatic and GI Neuroendocrine Tumors (pNETs)

Pancreatic and gastrointestinal neuroendocrine tumors occur in 60–70% of MEN1 patients and represent the leading cause of MEN1-related mortality. Unlike sporadic pNETs (which are typically solitary), MEN1-associated pNETs are characteristically multiple, small, and distributed throughout the pancreatic head, body, and tail. Non-functional pNETs — tumors that do not secrete a clinically detectable hormonal syndrome — are actually the most prevalent pancreatic tumors in MEN1, found in 40–80% of patients at autopsy or detailed imaging. Their clinical significance lies in malignant potential: large non-functional pNETs (greater than 2–3 cm) carry significant risk of hepatic metastasis and are a major driver of disease-specific mortality.

Gastrinoma and Zollinger-Ellison Syndrome — Gastrinoma is the most common functional pNET in MEN1, occurring in roughly 40% of patients and producing the dramatic Zollinger-Ellison syndrome (ZES): hypergastrinemia drives massive gastric acid hypersecretion, causing multiple peptic ulcers (often in atypical locations such as the distal duodenum or jejunum), diarrhea (from mucosal injury and bile acid inactivation), and acid-induced esophagitis. A critical anatomical nuance: despite the name "pancreatic gastrinoma," the majority of MEN1-associated gastrinomas actually arise in the wall of the duodenum (the submucosal gastrinoma triangle), not in the pancreas itself. They are typically small (less than 1 cm), multiple, and difficult to localize. Somatostatin receptor scintigraphy (Octreoscan) or 68Ga-DOTATATE PET/CT is superior to CT for detecting small gastrinomas. Biochemically, fasting serum gastrin above 1,000 pg/mL (with gastric pH below 2) is diagnostic of ZES; the secretin stimulation test (paradoxical gastrin rise of greater than 200 pg/mL after secretin injection) confirms the diagnosis in ambiguous cases. Medical management with high-dose proton pump inhibitors (often 60–80 mg of omeprazole or equivalent per day) effectively controls acid hypersecretion in most patients; surgical cure is far less achievable in MEN1-associated than in sporadic ZES due to multiplicity of tumors.

Insulinoma — Insulinoma occurs in approximately 10% of MEN1 patients and is the most common cause of hypoglycemia in this population. It produces autonomous insulin secretion, resulting in symptomatic fasting hypoglycemia. Whipple's triad — symptoms of hypoglycemia, documented low blood glucose (below 55 mg/dL), and relief of symptoms with glucose administration — remains the clinical cornerstone of diagnosis. Biochemically, elevated fasting insulin, C-peptide, and proinsulin in the setting of hypoglycemia confirm the diagnosis, while a negative sulfonylurea screen excludes factitious hypoglycemia. MEN1-associated insulinomas are often multiple. Surgical resection (distal pancreatectomy with or without enucleation of additional tumors in the pancreatic head) is the treatment of choice. Medical bridging with diazoxide or somatostatin analogs may be needed preoperatively or for inoperable cases.

Other Functional pNETs — VIPoma (vasoactive intestinal peptide-secreting tumor) causes profuse watery diarrhea, hypokalemia, and achlorhydria (Verner-Morrison syndrome or WDHA syndrome). Glucagonoma produces the classic glucagonoma syndrome: necrolytic migratory erythema (a distinctive skin rash), diabetes mellitus, weight loss, anemia, and venous thrombosis. PPoma (pancreatic polypeptide-secreting tumor) is technically non-functional in that elevated PP does not cause a clinical syndrome but serves as a useful tumor marker. These rarer functional pNETs each have distinct clinical and biochemical signatures that allow diagnosis before imaging localizes the culprit tumor.

Back to Table of Contents

Pituitary Adenomas

Pituitary adenomas occur in 30–40% of MEN1 patients. Although they are the third most common MEN1 feature, they are often among the most clinically impactful because they can cause both hormonal hypersecretion syndromes and mass effect on surrounding structures. MEN1-associated pituitary adenomas tend to be larger (macroadenomas) and more aggressive than sporadic counterparts, with a higher rate of invasion into surrounding bone and cavernous sinus.

Prolactinoma is the most common pituitary adenoma subtype in MEN1, accounting for approximately 60% of pituitary tumors in this setting. Excess prolactin causes hypogonadotropic hypogonadism: in women, amenorrhea, galactorrhea, and infertility; in men, decreased libido, erectile dysfunction, infertility, and gynecomastia. The first-line treatment is a dopamine agonist — cabergoline (preferred over bromocriptine due to superior efficacy and tolerability) — which suppresses prolactin secretion and often causes significant tumor shrinkage. Surgical transsphenoidal resection is reserved for dopamine agonist-resistant or intolerant cases.

GH-secreting adenomas (somatotropinomas) cause acromegaly in adults (or gigantism if growth plates are still open in adolescents): coarsening of facial features, acral enlargement (hands and feet), hyperhidrosis, arthropathy, sleep apnea, cardiomegaly, and glucose intolerance. Diagnosis rests on failure of GH suppression during an oral glucose tolerance test (GH nadir above 0.4 ng/mL) combined with elevated IGF-1 adjusted for age and sex. Transsphenoidal surgery is first-line; somatostatin analogs (octreotide LAR, lanreotide) and the GH receptor antagonist pegvisomant are used for residual or recurrent disease.

ACTH-secreting adenomas (corticotropinomas) cause Cushing's disease, the most severe hormonal syndrome arising from the pituitary in MEN1. Clinical features include central obesity, purple striae, proximal myopathy, hypertension, hyperglycemia, easy bruising, and osteoporosis. Diagnosis requires demonstration of ACTH-dependent hypercortisolism (elevated late-night salivary cortisol, 24-hour urine free cortisol, and failure of suppression with low-dose dexamethasone), followed by petrosal sinus sampling when needed to confirm pituitary origin. Transsphenoidal resection is the treatment of choice.

Non-functional pituitary adenomas do not cause hormonal syndromes but can produce mass effect: visual field deficits (classically bitemporal hemianopia from compression of the optic chiasm), headache, and hypopituitarism from compression of normal pituitary tissue. Transsphenoidal resection is indicated for progressive visual compromise or tumor growth.

Back to Table of Contents

Other Manifestations

MEN1 produces a range of tumors and lesions beyond the classic triad that clinicians must recognize both for their independent clinical impact and as diagnostic clues when the classic triad is incomplete.

Adrenal Cortical Adenomas — Adrenal adenomas or hyperplasia occur in approximately 25% of MEN1 patients, usually detected incidentally on abdominal imaging performed for pNET surveillance. The great majority are non-functional (not secreting cortisol, aldosterone, or androgens in excess), and the adrenal lesions of MEN1 are not pheochromocytomas (which are the adrenal hallmark of MEN2). Functional adrenal adenomas causing Cushing's syndrome or hyperaldosteronism do occur in MEN1 but are uncommon. Management follows standard incidentaloma guidelines: biochemical evaluation for subclinical hormonal excess and serial size monitoring, with adrenalectomy reserved for functional tumors or lesions showing worrisome growth or size above 4–6 cm.

Foregut Carcinoids — Carcinoid tumors arising from foregut-derived tissue represent a clinically important and potentially life-threatening non-classic MEN1 manifestation. Bronchial carcinoids (in the lung) are more common in women with MEN1, while thymic carcinoids are predominantly found in men. Thymic carcinoids deserve particular emphasis: they are more aggressive than bronchial carcinoids, can metastasize to lymph nodes and distant organs, and smoking dramatically increases the risk of thymic carcinoid development in MEN1 males — making smoking cessation a uniquely compelling imperative in this patient population, not merely a general health recommendation. Annual chest CT surveillance is standard in MEN1. Resection is indicated when thymic or bronchial carcinoids are detected. Unlike carcinoids in the general population, MEN1-associated thymic carcinoids rarely produce the carcinoid syndrome (flushing, diarrhea) and more often present as asymptomatic chest masses or incidental findings.

Cutaneous Manifestations — Skin lesions are found in more than 85% of MEN1 patients and are considered pathognomonic for the syndrome. The three characteristic lesions are: (1) multiple facial angiofibromas — small, flesh-colored or pink papules on the nose and upper lip indistinguishable from the angiofibromas of tuberous sclerosis; (2) collagenomas — flesh-colored connective tissue nevi, typically on the trunk; and (3) lipomas — soft subcutaneous fat deposits that may be multiple. These cutaneous findings are clinically benign but their presence in a young patient with hypercalcemia or peptic ulcer disease should immediately raise suspicion for MEN1 and prompt genetic evaluation. Dermatologists occasionally identify MEN1 before endocrinologists are involved.

Back to Table of Contents

Diagnosis and Surveillance

The clinical diagnosis of MEN1 is established when a patient develops two or more of the three primary component tumors (parathyroid, pNET, pituitary). A patient with one component tumor and a first-degree relative with MEN1 also meets diagnostic criteria. Genetic MEN1 (or presymptomatic MEN1) is defined by the identification of a germline MEN1 mutation in an individual who may not yet have developed clinical tumors.

Germline MEN1 gene sequencing identifies a pathogenic mutation in approximately 70–90% of clinically diagnosed cases. Over 1,300 distinct mutations have been catalogued, most causing loss of function through frameshift or nonsense mechanisms. When standard sequencing is negative in a patient with a strong clinical phenotype, large deletion/duplication analysis (using MLPA or array CGH) can identify whole-exon deletions that coding-sequence analysis misses. Negative genetic testing does not rule out MEN1 in patients fulfilling clinical criteria.

Biochemical Surveillance in confirmed mutation carriers begins in childhood, typically at age 5–10 years, and continues annually for life. The recommended annual panel includes: serum calcium and intact PTH (parathyroid); fasting glucose and fasting insulin (insulinoma); fasting serum gastrin (gastrinoma, checked off PPIs if safe); prolactin; and IGF-1 with GH (pituitary). Chromogranin A serves as a general neuroendocrine tumor marker but lacks specificity.

Imaging Surveillance complements biochemical monitoring. Pituitary MRI is recommended every 3–5 years in mutation carriers with normal biochemistry, or every 1–2 years after pituitary adenoma detection. Pancreatic and abdominal MRI or CT is recommended every 1–3 years, beginning at age 20. Chest CT (for bronchial and thymic carcinoids) is recommended every 1–2 years. Functional imaging with 68Ga-DOTATATE PET/CT has largely supplanted conventional somatostatin receptor scintigraphy for detection of small pNETs and carcinoids, offering superior sensitivity and spatial resolution.

Back to Table of Contents

Treatment

Treatment of MEN1 is individualized and tumor-specific, guided by the hormone secreted, tumor size, malignant potential, and the patient's overall tumor burden.

Parathyroid Disease — Surgical intervention is preferred for MEN1-associated PHPT when calcium is above 1 mg/dL above the upper limit of normal, when nephrolithiasis or osteoporosis is present, or when the patient is symptomatic. Bilateral neck exploration is required to assess all four glands. Subtotal parathyroidectomy (removing 3.5 glands and leaving a well-vascularized 50 mg remnant in the neck) and total parathyroidectomy with heterotopic autotransplantation into the brachioradialis muscle of the non-dominant forearm are the two accepted approaches. Both carry higher recurrence rates than sporadic PHPT surgery. Cinacalcet, a calcimimetic that allosterically activates the CaSR on parathyroid cells, can reduce calcium in patients who decline surgery or have recurrent disease, but does not address tumor growth.

Gastrinoma and Zollinger-Ellison Syndrome — High-dose proton pump inhibitor therapy (omeprazole 60–80 mg/day or equivalent in divided doses, titrated to achieve gastric pH above 4) effectively controls acid hypersecretion and heals peptic ulcers in the great majority of patients. PPIs have transformed the prognosis of ZES: patients who previously died of intractable peptic ulcer disease now die of malignant gastrinoma, if at all. Surgical resection of MEN1-associated gastrinoma is complex: because most lesions are multiple and duodenal, biochemical cure rates with surgery are far lower than for sporadic gastrinoma, and the procedure carries perioperative risk. Many centers reserve surgery for large (greater than 2 cm) or growing tumors with malignant potential. Somatostatin analogs (octreotide, lanreotide) are used for gastric acid control refractory to PPIs and for anti-proliferative management of metastatic disease.

Insulinoma — Surgical resection is definitive. Distal pancreatectomy with enucleation of identifiable tumors in the pancreatic head is the usual approach. Preoperative endoscopic ultrasound, combined with 68Ga-DOTATATE PET, improves tumor localization. Intraoperative ultrasound is invaluable for identifying small lesions invisible on the pancreatic surface. Diazoxide (inhibits insulin secretion via potassium channel opening) and somatostatin analogs control hypoglycemia in patients awaiting surgery or with inoperable disease.

Non-functional pNETs — Tumors above 2 cm carry significant malignant potential and are generally resected. Tumors below 2 cm are managed with watchful waiting and interval imaging given the high prevalence of small non-functional pNETs in MEN1 and the risks of repeated pancreatic surgery. Everolimus (mTOR inhibitor) and sunitinib (tyrosine kinase inhibitor) are approved for progressive, unresectable, or metastatic pNETs and are options when surgery is not feasible.

Pituitary Adenomas — Prolactinoma is managed first with dopamine agonists (cabergoline 0.5–3.0 mg weekly; bromocriptine as alternative). GH-secreting adenomas are treated with transsphenoidal surgery as the primary approach, followed by somatostatin analogs (octreotide LAR or lanreotide autogel) for residual disease, with pegvisomant (GH receptor antagonist) added for inadequate IGF-1 normalization. Cushing's disease from ACTH-secreting adenomas requires transsphenoidal resection; persistent or recurrent hypercortisolism is managed with bilateral adrenalectomy, steroidogenesis inhibitors (metyrapone, ketoconazole), or pasireotide. Non-functional pituitary macroadenomas are resected when they cause visual compromise, and monitored with serial MRI when small and asymptomatic.

Back to Table of Contents

Prognosis and Genetic Counseling

The prognosis of MEN1 has improved substantially with modern biochemical surveillance, which detects tumors at smaller sizes before malignant transformation or hormone hypersecretion cause irreversible organ damage. Nevertheless, MEN1 remains associated with reduced life expectancy compared to the general population. Disease-specific mortality is driven primarily by malignant pNETs (particularly non-functional pNETs with hepatic metastasis and thymic carcinoids) rather than by the hormonally active tumors, which are generally detectable and treatable. Population registry data from France and other countries indicate a median age of death in MEN1 patients of approximately 55–60 years, compared to 70+ years in age-matched controls, though more recent cohorts managed with systematic surveillance are doing better.

Thymic carcinoids in MEN1 males who smoke represent a particularly aggressive and largely preventable cause of death. The combination of MEN1 predisposition and tobacco carcinogen exposure dramatically amplifies thymic carcinoid risk; aggressive smoking cessation counseling is a potentially life-saving intervention in this group.

Genetic counseling is an essential component of MEN1 care. The condition is autosomal dominant with near-complete penetrance, meaning that each first-degree relative of an affected individual has a 50% probability of carrying the germline mutation. Genetic testing should be offered to all first-degree relatives, including children (testing in childhood is justified because parathyroid disease can manifest in the first decade and annual biochemical surveillance from age 5–10 is recommended for mutation carriers). Prenatal testing and preimplantation genetic diagnosis are available options for affected individuals who wish to prevent transmission. Psychological support and peer connections through patient advocacy organizations (such as the Association for Multiple Endocrine Neoplasia Disorders, AMEND) are important adjuncts to clinical management.

Back to Table of Contents

Key Research Papers

  1. Chandrasekharappa SC et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997. PMID: 11565070
  2. Thakker RV et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012. PMID: 19568104
  3. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 2014. PMID: 22723318
  4. Lemmens I et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet 1997. PMID: 9789085
  5. Jensen RT et al. Gastrinoma (Zollinger-Ellison syndrome). Best Pract Res Clin Gastroenterol 2008. PMID: 18165334
  6. Alrezk R et al. MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer 2017. PMID: 27386745
  7. Falconi M et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms. Neuroendocrinology 2012. PMID: 24700898
  8. Kamilaris CDC, Stratakis CA. Multiple endocrine neoplasia type 1 (MEN1): An update and the significance of early genetic and clinical diagnosis. Front Endocrinol 2019. PMID: 30089613
  9. Giusti F et al. Multiple endocrine neoplasia type 1 (MEN1). Ann Endocrinol 2013. PMID: 25105164
  10. Marini F et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis 2006. PMID: 16357026
  11. Goudet P et al. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 patients. World J Surg 2009. PMID: 23756736
  12. Ito T et al. Epidemiological trends of MEN1 in Japan from 2010 to 2014. Endocr J 2019. PMID: 31352529

Back to Table of Contents

Connections

Back to Table of Contents